Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

Background Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and heterogeneous. Our study aims at exploring and comp...

Full description

Bibliographic Details
Main Authors: Nerina Denaro, Lisa Licitra, Marco Merlano, Francesco Perri, Paolo Bossi, Cristina Gurizzan, Federica Perrone, Athanassios Argiris, Loris De Cecco, Stefano Cavalieri, Mara Serena Serafini, Federico Pistore, Deborah Lenoci, Silvana Canevari, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Grasic Kuhar, Andrea Vingiani, Maria Grazia Ghi, Alessandra Cassano, Giacomo Allegrini
Format: Article
Language:English
Published: BMJ Publishing Group 2024-01-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/1/e007823.full

Similar Items

Similar Items